Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been given a $136.00 target price by SunTrust Banks, Inc. in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. SunTrust Banks, Inc.’s target price would indicate a potential upside of 11.82% from the stock’s previous close.
A number of other equities research analysts have also recently weighed in on ZBH. Oppenheimer Holdings, Inc. set a $137.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Monday, August 14th. BidaskClub downgraded Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. BMO Capital Markets lifted their target price on Zimmer Biomet Holdings from $136.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Gabelli assumed coverage on Zimmer Biomet Holdings in a research report on Thursday, August 24th. They set a “buy” rating and a $142.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $136.55.
Zimmer Biomet Holdings (NYSE ZBH) traded down 4.32% during midday trading on Wednesday, reaching $116.37. 3,426,753 shares of the company’s stock traded hands. The stock has a market cap of $23.53 billion, a PE ratio of 33.14 and a beta of 1.19. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The stock’s 50 day moving average price is $118.31 and its 200-day moving average price is $120.47.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its quarterly earnings results on Monday, October 30th. The medical equipment provider reported $1.72 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. During the same period in the prior year, the business posted $1.79 EPS. Zimmer Biomet Holdings’s revenue for the quarter was down .8% compared to the same quarter last year. Equities analysts predict that Zimmer Biomet Holdings will post $8.23 earnings per share for the current year.
Large investors have recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. boosted its position in shares of Zimmer Biomet Holdings by 25.3% during the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 827 shares of the medical equipment provider’s stock valued at $106,000 after acquiring an additional 167 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Zimmer Biomet Holdings by 3.9% in the second quarter. Parkside Financial Bank & Trust now owns 872 shares of the medical equipment provider’s stock valued at $112,000 after buying an additional 33 shares in the last quarter. BB&T Investment Services Inc. acquired a new position in Zimmer Biomet Holdings in the second quarter valued at about $144,000. Parallel Advisors LLC boosted its position in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. Finally, IHT Wealth Management LLC boosted its position in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Institutional investors own 85.26% of the company’s stock.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.